Streetbeat News

Analyst Ratings

VFC

Wedbush analyst Tom Nikic maintains a Neutral rating on VF Corporation (VFC) and lowers the price target from $16.5 to $15.5.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:26 pm

RLYB

Wedbush analyst Laura Chico maintains an Outperform rating on Rallybio (NASDAQ:RLYB) but lowers the price target from $14 to $13.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:23 pm

SHOO

Wedbush analyst Tom Nikic has maintained a Neutral rating on Steven Madden (NASDAQ:SHOO) and increased the price target from $36 to $38.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:21 pm

YUMC

Yum China Holdings, Inc. (NYSE:YUMC) shares surged over 14% in premarket trading following strong fourth-quarter results, a $1.25 billion stock buy-back announcement, and a 23% increase in cash dividend. The company reported a 21% rise in system sales, a 170% jump in operating profit, and a 324% increase in core operating profit. Yum China plans to open 1,500 to 1,700 new stores by 2026 and return at least $3 billion to shareholders. Despite this, JP Morgan downgraded Yum China to Neutral from Overweight.

Portfolio Pulse from Nabaparna Bhattacharya

February 07, 2024 | 1:19 pm

UBER

Needham analyst Bernie McTernan reiterated a Buy rating on Uber Technologies (NYSE:UBER) and maintained a $71 price target.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:19 pm

SONO

Analysts have updated their ratings and price targets for Sonos (NASDAQ:SONO), showing a mix of bullish and somewhat bullish opinions. The average 12-month price target has been raised to $20.25, indicating a positive sentiment shift. Sonos's financials reveal challenges, with a -3.52% revenue decline and below-industry-standard profitability metrics. Despite this, the updated analyst ratings and higher price targets suggest a cautiously optimistic outlook for the stock.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 1:01 pm

ALTM

Arcadium Lithium (NYSE:ALTM) has received mixed analyst ratings over the past quarter, with a significant drop in the average 12-month price target from $19.00 to $6.97. Analysts from firms like Piper Sandler, JP Morgan, and Raymond James have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Arcadium Lithium, emerging from the Allkem-Livent merger, is a key player in the lithium market, crucial for EV batteries. Despite facing revenue growth challenges, the company exhibits strong financial health indicators such as high net margin and ROE.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 1:01 pm

MMSI

Merit Medical Systems (NASDAQ:MMSI) has seen varied analyst opinions over the past three months, with recent updates showing a positive shift in price targets. The average 12-month price target has risen to $92.75, up 12.19% from $82.67. Analysts from B of A Securities, Raymond James, Piper Sandler, and Canaccord Genuity have updated their ratings and price targets, reflecting optimism about the company's performance. Merit Medical Systems, a medical equipment company, has shown a revenue growth of 9.77% and a net margin of 8.2%, outperforming industry standards.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 1:01 pm

FDMT

4D Molecular Therapeutics (NASDAQ:FDMT) has received diverse analyst ratings over the past quarter, with a recent shift towards a more bullish outlook. The latest ratings include one bullish and three somewhat bullish, with an average 12-month price target of $52.75, marking a significant increase from the previous $37.50. Analysts from Goldman Sachs, BMO Capital, and RBC Capital have adjusted their price targets and ratings, reflecting optimism about the company's future performance. 4D Molecular Therapeutics, a clinical-stage gene therapy company, has shown impressive revenue growth and financial performance, with a notable market capitalization, revenue growth rate of 3940.8%, and strong profitability indicators such as net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 1:00 pm

BJ

Analyst ratings for BJ's Wholesale Club (NYSE:BJ) over the past three months have been consistently indifferent, with all five analysts giving a neutral stance. The average 12-month price target has been adjusted to $67.8, down from $71.00, indicating a 4.51% decline. The company's financial performance shows positive revenue growth and strong profitability metrics, despite a high debt-to-equity ratio. Analysts from firms including Gordon Haskett, Wells Fargo, Citigroup, Roth MKM, and Evercore ISI Group have provided recent evaluations, with price targets ranging from $63.00 to $72.00.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 1:00 pm